We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exact Sciences (EXAS) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
Exact Sciences (EXAS - Free Report) closed at $87.93 in the latest trading session, marking a -1.83% move from the prior day. This move lagged the S&P 500's daily loss of 1.57%. Elsewhere, the Dow lost 1.57%, while the tech-heavy Nasdaq lost 1.89%.
Heading into today, shares of the molecular diagnostics company had lost 6.51% over the past month, lagging the Medical sector's loss of 1.74% and the S&P 500's gain of 2.35% in that time.
EXAS will be looking to display strength as it nears its next earnings release. On that day, EXAS is projected to report earnings of -$0.34 per share, which would represent year-over-year growth of 22.73%. Our most recent consensus estimate is calling for quarterly revenue of $294.63 million, up 106.07% from the year-ago period.
Investors should also note any recent changes to analyst estimates for EXAS. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 4.03% higher. EXAS is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 88, putting it in the top 35% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Exact Sciences (EXAS) Dips More Than Broader Markets: What You Should Know
Exact Sciences (EXAS - Free Report) closed at $87.93 in the latest trading session, marking a -1.83% move from the prior day. This move lagged the S&P 500's daily loss of 1.57%. Elsewhere, the Dow lost 1.57%, while the tech-heavy Nasdaq lost 1.89%.
Heading into today, shares of the molecular diagnostics company had lost 6.51% over the past month, lagging the Medical sector's loss of 1.74% and the S&P 500's gain of 2.35% in that time.
EXAS will be looking to display strength as it nears its next earnings release. On that day, EXAS is projected to report earnings of -$0.34 per share, which would represent year-over-year growth of 22.73%. Our most recent consensus estimate is calling for quarterly revenue of $294.63 million, up 106.07% from the year-ago period.
Investors should also note any recent changes to analyst estimates for EXAS. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 4.03% higher. EXAS is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 88, putting it in the top 35% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.